• Cognito Therapeutics

  Participated · Series C · Mar 2026

  Cognito Therapeutics is a clinical-stage neurotechnology firm focused on creating neuroprotective, non-invasive therapies for central nervous system disorders. Its lead product, Spectris, is an at-home therapeutic platform that delivers sensory-driven neurostimulation to synchronize neural activity across interconnected brain networks. Feasibility studies indicate Spectris may preserve cognition, maintain daily function, and slow brain atrophy in patients with mild-to-moderate Alzheimer’s disease. The company plans to expand the Spectris platform into additional neurodegenerative indications through a network of brain-health collaboratories, beginning with the WVU Rockefeller Neuroscience Institute. Proceeds from its latest financing will fund these clinical expansions and further platform development. Although specific revenue or user numbers were not disclosed, the company positions itself as a late clinical-stage player nearing pivotal trials.

No current team members are available.